New Lung Cancer Treatments Show Landmark Survival Gains : A Turning Point for Patients
New data released around the 2026 World Conference on Lung Cancer point to meaningful progress in treating difficult cancers. Johnson & Johnson reported final overall-survival results from the phase 3 PAPILLON study of RYBREVANT plus chemotherapy for previously untreated non-small cell lung cancer with EGFR exon 20 insertion mutations. The company described the findings as the longest reported median overall survival for this patient population. Johnson & Johnson
The news comes alongside an eight-year update for AstraZeneca’s TAGRISSO. In the ADAURA trial, adjuvant TAGRISSO after surgery reduced the risk of death by 47% in the primary stage II–IIIA population; an estimated 74% of patients receiving TAGRISSO were alive at eight years, compared with 58% receiving placebo. AstraZeneca
For patients, the broader message is that tumor testing can matter. EGFR results may help doctors identify targeted treatment options, while clinical-trial findings can shape future standards of care. BioNTech also reported that investigational gotistobart produced median overall survival of 18.5 months versus 10 months with docetaxel in a phase 3 study of relapsed squamous NSCLC. The trial remains ongoing, so the medicine is not yet an approved standard. BioNTech
Another important development affects people with polycythemia vera. The FDA approved Mimrylo (rusfertide) on August 28, 2026, after a trial found that 76.9% of treated patients avoided phlebotomy during the evaluation period, compared with 32.9% on placebo. FDA
Patients should discuss biomarker testing, treatment risks, and trial eligibility with their care teams. Which medical breakthroughs would you like Brownstone Worldwide to explain next?
